2026 IPO stock tracker: How newly public biotechs are performing
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Biopharma Mergers & Acquisitions
Biopharma Mergers & Acquisitions
Live Last read · last published · next check
Latest posts
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.
Rebounding biotech funds expected to spur CDMO growth within year
With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms.
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of dollars’ worth of deals his company has struck.
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.